Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

Also called NCT05995600

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05995600
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05995600. Randomized; single masking; primary purpose prevention. Start 2024-02-20 (actual); primary completion 2029-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
Acronym
APS-STROKE
Condition
Antiphospholipid Syndrome
Condition
Cerebrovascular Disease
Condition
Cardiovascular Diseases
Condition
Major Bleed
Intervention (Drug)
Antiplatelet Drug
Intervention (Drug)
Warfarin
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Samjin Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05995600
Content hash
9594edc5685336a111cb05c5d833082abca65e812de0e912c612efa5ff33d20d